J&J COVID-19 vaccine in limbo as U.S. panel delays vote on resuming shots
WASHINGTON (Reuters) - Johnson & Johnson's COVID-19 vaccine remained in limbo on Wednesday evening as a U.S. health panel called for more data before making a decision on how and whether to resume use of the one-dose shot, putting off a vote for a week or more.